ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 277 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,367 | -95.2% | 12,578 | -94.6% | 0.00% | -90.0% |
| Q2 2023 | $7,126,116 | -13.6% | 231,819 | +1.3% | 0.01% | -16.7% |
| Q1 2023 | $8,247,086 | -9.0% | 228,895 | -0.1% | 0.01% | -14.3% |
| Q4 2022 | $9,058,537 | +5.0% | 229,214 | +6.8% | 0.01% | 0.0% |
| Q3 2022 | $8,625,000 | -11.3% | 214,661 | -7.1% | 0.01% | -6.7% |
| Q2 2022 | $9,721,000 | +27.9% | 230,954 | +18.5% | 0.02% | +50.0% |
| Q1 2022 | $7,599,000 | +14.0% | 194,849 | +16.4% | 0.01% | +11.1% |
| Q4 2021 | $6,668,000 | +28.6% | 167,332 | +16.6% | 0.01% | +12.5% |
| Q3 2021 | $5,187,000 | -12.7% | 143,530 | -1.0% | 0.01% | +14.3% |
| Q2 2021 | $5,941,000 | -4.1% | 144,928 | +2.0% | 0.01% | -12.5% |
| Q1 2021 | $6,196,000 | -49.4% | 142,034 | -41.9% | 0.01% | -11.1% |
| Q4 2020 | $12,240,000 | +132.1% | 244,564 | +97.0% | 0.01% | +12.5% |
| Q3 2020 | $5,273,000 | +11.3% | 124,169 | +27.2% | 0.01% | -11.1% |
| Q2 2020 | $4,739,000 | – | 97,606 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |